Science & ResearchJul 23, 2026
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer.
Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin-pembrolizumab as compared with neoadjuvant cisplatin-based chemotherapy in persons with this…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.